Beyond Vaccines: checkpoint drugs, precision therapy, and why combinations win.

Reading the tumor: precision oncology

For decades, chemotherapy was chosen by cancer type, not by the individual tumor. Precision oncology changes that. A lab sequences the tumor's DNA, finds the specific mutations driving it, and matches those mutations to targeted drugs, often oral pills, designed to block the exact pathway the cancer depends on. Several companies offer this for dogs today, and the newer tests also report the tumor's overall mutation load.

Here is what that sequencing actually finds in hemangiosarcoma. In the largest such study, according to PubMed, 109 dogs with splenic HSA had their tumors profiled, and the most common mutations were in three genes: TP53, NRAS, and PIK3CA (Estabrooks et al., Veterinary and Comparative Oncology, 2023).

The most common mutations in hemangiosarcoma

Share of tumors carrying each mutation, 109 dogs with splenic HSA

That last point matters. Notice that even TP53, the most common, shows up in only about 40% of tumors, and many dogs carry none of the three. So precision oncology can find a targetable mutation in some dogs, but not most, and there is a second catch: cancers mutate continuously, so a targeted drug that works at first tends to stop working as the tumor evolves around it. This is why targeted therapy is increasingly paired with immunotherapy rather than used alone. Ask your oncologist whether tumor profiling makes sense for your dog, and treat any oral targeted drug it turns up as one tool among several, not a standalone answer.

Releasing the brakes: checkpoint inhibitors

Cancer does not just hide from the immune system. It actively shuts it down. One of its favorite tricks is to press a built-in "off switch" on the immune system's killer cells. Those cells carry a receptor called PD-1, and when a matching molecule (PD-L1) on the cancer touches it, the killer cell powers down. The cancer, in effect, tells the immune system to stand down, and it obeys.

A checkpoint inhibitor blocks that handshake, so the immune cells stay switched on. In human medicine, these drugs (Keytruda is the famous one) are behind many of the headline immunotherapy successes. A canine version exists, an anti-PD-1 antibody sometimes described as a "canine Keytruda," and it is being tested in hemangiosarcoma in combination with a vaccine, with early survival results reported at conferences (not yet peer-reviewed). The honest limitation is cost: a full course can run ten to twenty thousand dollars depending on the dog's size, which puts it out of reach for many families. It is a powerful idea whose price tag is, for now, a real barrier.

A toxin built for this cancer: eBAT

Not every promising result for hemangiosarcoma is a vaccine. One of the most encouraging comes from a targeted toxin called eBAT, engineered to home in on two markers found on both hemangiosarcoma cells and the blood vessels that feed them, then poison them specifically. Because it hits the tumor and its blood supply at once, it is unusually well-suited to a blood-vessel cancer.

In a study of 23 dogs with splenic hemangiosarcoma, according to PubMed, dogs received one cycle of eBAT after splenectomy and before standard chemotherapy. At the effective dose, six-month survival improved from under 40% in a comparison group to about 70%, and six dogs became long-term survivors, living more than 450 days (Borgatti et al., Molecular Cancer Therapeutics, 2017).

A targeted toxin, built for hemangiosarcoma

Share of dogs alive at six months, splenic HSA

Low-cost add-ons worth asking about

Three inexpensive, low-side-effect ideas come up often. All are plausible, none is proven in hemangiosarcoma, and it is worth knowing exactly how thin the evidence is for each.

Propranolol

Propranolol is a cheap, decades-old blood-pressure drug. Its cancer story began by accident: doctors noticed that babies with benign blood-vessel growths (hemangiomas) saw them shrink dramatically when given propranolol for an unrelated reason (Léauté-Labrèze et al., New England Journal of Medicine, 2008). Since hemangiosarcoma is also a blood-vessel disease, the reasoning goes, perhaps propranolol could help there too. The canine evidence so far is only case-report grade, a handful of dogs, uncontrolled (Terauchi et al., 2023). So: mechanistically reasonable, cheap, low-risk, and unproven. Worth a conversation with your vet, not a guarantee.

The gut microbiome

The community of bacteria in the gut turns out to influence how well both chemotherapy and immunotherapy work, in humans and in mice. That has sparked interest in improving a dog's microbiome, including with oral fecal-transplant capsules now sold for dogs. This is early and unproven for hemangiosarcoma specifically, but it is low-risk and an active research area.

Timing of treatment

Here is a genuinely surprising one. In people, immunotherapy infusions given earlier in the day appear to work better than the same drug given in the late afternoon (Qian et al., The Lancet Oncology, 2021). This is retrospective human data on checkpoint inhibitors, not a canine trial, so it is a hypothesis rather than a rule. But it costs nothing to schedule a morning appointment, so it is a fair thing to raise.

Why combinations win, and the chemo surprise

Step back from the individual tools and one pattern dominates the entire field: no single treatment cures hemangiosarcoma, and the better outcomes come from combinations. A vaccine plus a checkpoint drug. A targeted toxin plus chemotherapy. Immunotherapy layered onto surgery. The immune system is a system, and it tends to respond best when it is nudged in several ways at once.

That leads to a genuinely counterintuitive idea about chemotherapy. We tend to assume more chemo is stronger medicine. But chemotherapy does something beyond killing cancer cells: when it kills them in the right way, it spills their contents out where the immune system can learn from them, a phenomenon called immunogenic cell death. In effect, a well-timed dose of chemo can act like a free vaccine, teaching the immune system what the cancer looks like. Too much chemo, though, also wipes out the very immune cells you are trying to recruit.

The most striking hint of this came from the bone-cancer immunotherapy we met in Part 3. When its makers looked closely at their data, the dogs that received a single dose of chemotherapy alongside the immunotherapy did markedly better than dogs that received the standard four doses. More chemo was not better. It may even have been worse. That is only a hint from one dataset, not a rule to act on, but it points at something important: the goal may be the optimal amount of chemotherapy for the immune system, not the maximum the dog can tolerate.

What this means for your dog

• Ask about tumor profiling if you are considering targeted drugs, but keep expectations honest: a useful mutation is found in some dogs, not most.
• Checkpoint inhibitors are promising but expensive. Worth asking about, worth knowing the price before you get attached to the idea.
• The low-cost add-ons (propranolol, microbiome support, morning appointments) are reasonable to raise precisely because they are cheap and low-risk, as long as you hold them as unproven.
• Favor a thoughtful combination over any single "best" treatment, and ask your oncologist about chemotherapy dose and timing, not just whether to do it.

Every one of these belongs in a conversation with a licensed veterinary oncologist who knows your dog's specific case.

A note on sources

This series was prompted by a public educational webinar from the Canine Cancer Alliance, a nonprofit that funds canine cancer research. Peer-reviewed claims are cited to their original studies by DOI or PubMed. Where evidence is early, human-only, or case-report grade, we label it plainly, because with this cancer the strength of the evidence is the whole story.